zilovertamab vedotin (MK-2140) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zilovertamab vedotin (MK-2140) / Merck (MSD)
waveLINE-010, NCT06717347: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
3
1046
US
Zilovertamab vedotin, MK-2140, VLS-101, Rituximab, RITUXAN®, Cyclophosphamide, CYTOXAN®, NEOSAR®, Doxorubicin, ADRIAMYCIN®, Rituximab Biosimilar, TRUXIMA®, RUXIENCE®, RIABNI®, Prednisone, Prednisolone, Vincristine
Merck Sharp & Dohme LLC
Diffuse Large B-Cell Lymphoma
03/32
03/32
2021-003313-18: A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate the most effective dose and the safety of medication MK-2140 when combined with standard treatments in patients with Diffuse Large B-Cell Lymphoma who failed prior therapies.

Ongoing
2/3
420
Europe
Zilovertamab Vedotin, Gemcitabine hydrochloride, Bendamustine Chydrochloride, Oxaliplatin, MK-2140, Solution for injection, Powder for solution for infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Gemcitabine SUN, Bendamustin medac, Oxaliplatin AqVida, MabThera 100mg, MabThera 500 mg
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (a type of non-Hodgkin's lymphoma, in patients who failed prior therapies), Diseases [C] - Cancer [C04]
 
 
waveLINE-003, NCT05139017 / 2021-003313-18: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Recruiting
2/3
290
Europe, Canada, US, RoW
Zilovertamab vedotin, MK-2140, VLS-101, Rituximab, Rituxan®/mabthera, Truxima® (rituximab-abbs), RUXIENCE®), Gemcitabine, Gemzar®, Oxaliplatin, Eloxatin®, Bendamustine, Bendeka®, Treanda®, Belrapzo®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
DLBCL, Diffuse Large B-Cell Lymphoma
09/27
09/27
2021-003397-32: A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies. Estudio de investigación en el que los participantes y personal sanitario saben qué tratamiento se está recibiendo, para evaluar la seguridad y eficacia de MK-2140 en pacientes con linfoma difuso de células B grandes que no hayan respondido a terapias anteriores.

Not yet recruiting
2
100
Europe, RoW
Zilovertamab Vedotin, MK-2140, Solution for injection
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., Merck Sharp & Dohme LLC., a subsidiary of Merck & Co.,Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC,
Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Tratamiento en participantes con linfoma difuso de células B grandes en recaída o resistente, Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in patients who failed prior therapies) Linfoma difuso de células B grandes (un tipo de linfoma No Hodgkin) en pacientes que hayan fallado en terapias previas, Diseases [C] - Cancer [C04]
 
 
2021-005861-41: A research study to evaluate the safety and effectiveness and dosing of Zilovertamab Vedotin with R-CHP in adults with DLBCL Un estudio en investigación para evaluar la seguridad y eficacia y la dosificación de Zilovertamab Vedotin con R-CHP en adultos con LDCBG.

Ongoing
2
60
Europe
zilovertamab vedotin, Endoxan, Doxorubicin-Ebewe, Prednisone, Truxima, MK-2140, Lyophilisate for solution for infusion, Powder for solution for injection, Concentrate for solution for infusion, Tablet, Endoxan, Doxorubicin-Ebewe, Prednison 50 mg GALEN, Truxima
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Diffuse Large B-cell Lymphoma (DLBCL) Linfoma difuso de linfocitos B grandes (LDCBG), Phase II dose confirmation study in diffuse large B-cell lymphoma Estudio fase II de confirmación de dosis en Linfoma difuso de linfocitos B grandes., Diseases [C] - Cancer [C04]
 
 
2021-004450-36: A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malignancies Estudio para evaluar la seguridad y la eficacia de Zlovertamab Vedotin con o sin Nemtabrutinib y en aldultos con neoplasias malignas de linfocitos B.

Ongoing
2
260
Europe
Zilovertamab Vedotin, Nemtabrutinib, MK-2140, MK-1026, Lyophilisate for solution for infusion, Tablet
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Aggressive and Indolent B-cell Malignancies neoplasias linfoides B agresivas e indolentes, Phase II Signal Finding Study in B-Cell Malignancies Estudio de fase II de búsqueda de neoplasias linfoides B agresivas e indolentes., Diseases [C] - Cancer [C04]
 
 
MK-2140-002, NCT04504916: A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors

Terminated
2
102
Canada, US
Zilovertamab vedotin, MK-2140, VLS-101
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
06/23
06/23
waveLINE-004, NCT05144841: A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Active, not recruiting
2
140
Europe, Canada, US, RoW
MK-2140 (zilovertamab vedotin)
Merck Sharp & Dohme LLC
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
06/25
06/25
waveLINE-007, NCT05406401 / 2021-005861-41: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Active, not recruiting
2
60
Europe, Canada, RoW
Zilovertamab Vedotin, MK-2140, VLS-101, Cyclophosphamide, CYTOXAN®, NEOSAR®, Doxorubicin, ADRIAMYCIN®, Rituximab, RITUXAN®, Rituximab Biosimilar, TRUXIMA®, Prednisone, Prednisolone
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Lymphoma, Large B-Cell, Diffuse (DLBCL)
04/29
04/29
waveLINE-006, NCT05458297 / 2021-004450-36: A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Recruiting
2
223
Europe, Canada, Japan, US, RoW
Zilovertamab vedotin, MK-2140, Nemtabrutinib, MK-1026
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
03/27
04/27
2020-004544-28: Phase 1/2 Substudy of Investigation Agents in PD-1/L1 Refractory Locally Advanced (Inoperable) or Metastatic Urothelial (Bladder) Cancer Subestudio de fase 1/2 de fármacos en investigación en el cáncer urotelial (vejiga) localmente avanzado (inoperable) o metastásico resistente a inhibidores de PD-1/L1

Not yet recruiting
1/2
40
Europe
Zilovertamab vedotin, MK-2140, Lyophilisate for solution for infusion
Merck Sharp & Dohme LLC, MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC
Locally advanced or metastatic urothelial cancer Cáncer urotelial localmente avanzado o metastásico, Locally Advanced (inoperable) or metastatic urothelial (bladder) cancer Cáncer urotelial (vejiga) localmente avanzado (inoperable) o metastásico, Diseases [C] - Cancer [C04]
 
 
LIGHTBEAM-U01, NCT06395103: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/)

Recruiting
1/2
90
Europe, US, RoW
Zilovertamab vedotin, MK-2140, VLS-101
Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
03/29
03/29
KEYMAKER-U04 substudy 04A, NCT05562830: A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Active, not recruiting
1/2
40
Europe, US, RoW
Zilovertamab vedotin, MK-2140, VLS-101
Merck Sharp & Dohme LLC
Urothelial Carcinoma
10/27
10/27
waveLINE-001, NCT03833180: A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

Completed
1
91
US
Zilovertamab vedotin, VLS-101, MK-2140
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, Richter Transformation Lymphoma, Burkitt Lymphoma, Lymphoplasmacytoid Lymphoma, T-cell Non-Hodgkin Lymphoma, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Waldenstrom Macroglobulinemia
12/23
12/23

Download Options